NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $57.58 +0.40 (+0.70 %) (As of 01/17/2019 01:50 PM ET)Previous Close$57.18Today's Range$56.67 - $57.9152-Week Range$39.07 - $59.81Volume14,838 shsAverage Volume875,703 shsMarket Capitalization$8.01 billionP/E Ratio719.88Dividend YieldN/ABeta2.16 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California. Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS Previous Symbol CUSIP46433010 Webwww.ionispharma.com Phone760-931-9200Debt Debt-to-Equity Ratio0.74 Current Ratio7.99 Quick Ratio7.96Price-To-Earnings Trailing P/E Ratio719.88 Forward P/E Ratio-198.55 P/E GrowthN/A Sales & Book Value Annual Sales$507.67 million Price / Sales15.60 Cash Flow$0.3589 per share Price / Cash Flow160.43 Book Value$3.36 per share Price / Book17.14Profitability EPS (Most Recent Fiscal Year)$0.08 Net Income$-5,960,000.00 Net Margins-7.52% Return on Equity-1.58% Return on Assets-0.55%Miscellaneous Employees547 Outstanding Shares137,570,000Market Cap$8.01 billion OptionableOptionable Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.10. The firm had revenue of $145.40 million for the quarter, compared to analysts' expectations of $146.77 million. Ionis Pharmaceuticals had a negative return on equity of 1.58% and a negative net margin of 7.52%. The company's revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.02) EPS. View Ionis Pharmaceuticals' Earnings History. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Ionis Pharmaceuticals. What price target have analysts set for IONS? 7 brokerages have issued 12-month price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $46.00 to $75.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $53.7143 in the next year. This suggests that the stock has a possible downside of 6.7%. View Analyst Price Targets for Ionis Pharmaceuticals. What is the consensus analysts' recommendation for Ionis Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals. Has Ionis Pharmaceuticals been receiving favorable news coverage? Media coverage about IONS stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news impact score of 2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the next few days. Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY) and Sarepta Therapeutics (SRPT). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the folowing people: Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 74)Dr. Brett P. Monia, Founder, COO & Sr. VP of Translational Medicine (Age 58)Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 57)Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 61)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65) Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.27%), BLB&B Advisors LLC (0.18%) and First Hawaiian Bank (0.00%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals. Which institutional investors are selling Ionis Pharmaceuticals stock? IONS stock was sold by a variety of institutional investors in the last quarter, including BLB&B Advisors LLC and First Hawaiian Bank. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals. Which institutional investors are buying Ionis Pharmaceuticals stock? IONS stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $57.58. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $8.01 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe. What is Ionis Pharmaceuticals' official website? The official website for Ionis Pharmaceuticals is http://www.ionispharma.com. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200. MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 495 (Vote Outperform)Underperform Votes: 512 (Vote Underperform)Total Votes: 1,007MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: How is inflation measured?